Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: pz who wrote (2159)	2/2/2000 6:28:00 AM
From: Hank	Read Replies (2) \| Respond to of 5582

"...the results of a small pilot trial performed by Gel Tech..." Didn't this small "pilot" trial also involve about 100 patients? Yet, here they are claiming that: "The new study of over 100 patients was led by Dr. Michael Hirt...showed that patients given Zicam within 24 hours after the onset of cold symptoms had symptoms for about 2 days..." is statistically significant and conclusive??? Give me a break. This is another smoke and mirrors attempt to give themselves credibility. It is nothing more than a new twist on old data. There is absolutely nothing new in these press releases. Just the same old claims stated a different way. I wonder how many patients constitutes "over 100"? My guess is 101. Wow. Now there's some massive data to wade through. Unfortunately, it is STILL statistically insignificant given the number of people that suffer from colds every year and the 100+ serotypes of rhino virus that cause these colds. I can't wait to see what highly "respected" journal this gets published in- assuming it ever gets published at all.